FindTrial
Sign In

To compare effectiveness of Lorazepam and Risperidone in the treatment of Cannabis Induced Psychotic Disorder

Comparative efficacy of Lorazepam and Risperidone in Cannabis Induced Psychotic Disorder - CELRCIPD

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/05/033552
Enrollment
40
Registered
2021-05-11
Start date
Unknown
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F129- Cannabis use, unspecified

Interventions

Intervention1: Lorazepam 1mg-10mg per day, Risperidone 2mg-8mg per day: A total of 40 patients will be included in the study. After the initial work-up, the patients shall be randomly allocated to one

Sponsors

Government medical college and hospital Chandigarh
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients fulfilling the diagnostic criteria for cannabis induced psychotic disorder as per DSM-5. 18-65 years old Male patients. Patients willing for admission in ward for treatment. Patients who test positive for cannabinoids on urine screening. Patients with a reliable informant. Patients willing to give consent.

Exclusion criteria

Exclusion criteria: Patients with comorbid dependence on other substances except caffeine and nicotine. Patients having current comorbid major mental illness. Patients with a history of medical/physical illness where the use of Lorazepam/ Risperidone is contraindicated. For e.g. chronic liver disease, chronic kidney disease, chronic lung disease, head injury etc. History of hypersensitivity to Lorazepam/ Risperidone.

Design outcomes

Primary

MeasureTime frame
Reduction in the severity of psychopathology as assessed by the administration of various psychiatric rating scales like positive and negative syndrome scale (PANSS) and Young mania rating scale (YMRS) on a daily basis till 10 days after the initiation of treatment.Timepoint: positive and negative syndrome scale (PANSS) and Young mania rating scale (YMRS) shall be administered at baseline and, thereafter, daily for a period of 10 days.—

Secondary

MeasureTime frame
to assess the severity of dependence, evolution of withdrawal symptoms and craving using the severity of dependence scale (SDS), cannabis withdrawal scale (CWS) and marijuana craving questionnaire (MCQ) respectively.Timepoint: severity of dependence scale (SDS) shall be administered at baseline only. cannabis withdrawal scale (CWS) and marijuana craving questionnaire (MCQ) shall be applied at baseline and, thereafter, daily for a period of 10 days.—

Countries

India

Contacts

Public ContactArshdeep

Government medical college and hospital, Sector 32, Chandigarh

ajeetsidana@hotmail.com9646121614

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026